Korrektur
Correction to “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study”
Clinical Endocrinology · 2026-12 · 105 (6) · 680-681
DOI: 10.1111/cen.70207 ↗Kurz gefasst
Korrektur in der Zeitschrift Clinical Endocrinology, online erschienen am 15.09.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study”. Clinical Endocrinology, 105(6), 680-681. https://doi.org/10.1111/cen.70207
Vancouver
Correction to “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study”. Clinical Endocrinology. 2026;105(6):680-681. doi:10.1111/cen.70207
BibTeX
@article{euvimed2026,
title = {Correction to “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study”},
journal = {Clinical Endocrinology},
year = {2026},
volume = {105},
number = {6},
pages = {680--681},
doi = {10.1111/cen.70207}
}
EUVIMED